A Single Blind, Randomized, Placebo Control, Phase I Study to Evaluate the Safety and Immunogenicity of the GC1109 Administered by the Intramuscular Route in Healthy Men
Latest Information Update: 09 May 2019
At a glance
- Drugs GC 1109 (Primary)
- Indications Anthrax
- Focus Adverse reactions
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 21 Jun 2013 New trial record